Provided by Tiger Trade Technology Pte. Ltd.

ORUKA THERAPEUTICS INC

92.35
-0.2700-0.29%
Volume:139.20K
Turnover:12.74M
Market Cap:6.11B
PE:-45.62
High:93.20
Open:90.78
Low:90.59
Close:92.62
52wk High:115.52
52wk Low:14.67
Shares:66.21M
Float Shares:56.55M
Volume Ratio:0.71
T/O Rate:0.25%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.0242
EPS(LYR):-1.8483
ROE:-18.23%
ROA:-12.95%
PB:5.50
PE(LYR):-49.96

Loading ...

Oruka Therapeutics SVP Finance Arjun Agarwal Sells USD 840,975 in Common Shares

Reuters
·
Jul 14

13D Filings

Dow Jones
·
Jul 11

Movement Alert|Oruka Therapeutics Rises 6.18% in Regular Trading, UBS Bullish on H2 Clinical Data Catalyst for Lead Psoriasis Drug

Market Focus
·
Jul 08

Movement Alert|Oruka Therapeutics Falls 11.21% in Regular Trading, Trading at $83.215

Market Focus
·
Jul 03

Oruka Therapeutics falls -8.1%

TIPRANKS
·
Jul 02

Oruka Therapeutics COO Laura Lee Sandler Sells USD 472,784 in Common Shares

Reuters
·
Jul 02

Oruka Therapeutics H2 ORKA-001 Data Could Further De-Risk Lead Program, UBS Says

MT Newswires Live
·
Jul 01

Analysts Offer Insights on Healthcare Companies: Amgen (AMGN), Oruka Therapeutics (ORKA) and Hims & Hers Health (HIMS)

TIPRANKS
·
Jul 01

Stifel Nicolaus Remains a Buy on Oruka Therapeutics (ORKA)

TIPRANKS
·
Jun 29

Oruka Therapeutics (ORKA) Is Up 5.1% After Positive Trial Update And Insider Share Sales - What's Changed

Simply Wall St.
·
Jun 24

Oruka Therapeutics SVP Finance Arjun Agarwal disposes of 1,587 common shares worth $127,454.28

Reuters
·
Jun 23

Oruka Therapeutics CMO Joana Goncalves disposes of USD 552,429 common shares

Reuters
·
Jun 16

Oruka’s Expanded IL-23 Rights Reshape Pipeline Options And Partner Potential

Simply Wall St.
·
Jun 15

Oruka Therapeutics (ORKA) Stock Valuation After A 147% Year-To-Date Surge And 8.7x P/B Rating

Simply Wall St.
·
Jun 14

Oruka Therapeutics director Carl Dambkowski disposes of $2.46 million in common shares

Reuters
·
Jun 13

Is Oruka’s Broadened IL-23 License Reshaping Optionality And Altering The Investment Case For Oruka Therapeutics (ORKA)?

Simply Wall St.
·
Jun 07

Oruka Therapeutics shareholders elect Klein, Martin as Class II directors at annual meeting

Reuters
·
Jun 05

Piper Sandler Sticks to Their Buy Rating for Oruka Therapeutics (ORKA)

TIPRANKS
·
Jun 02

Oruka Therapeutics - Enters First Amendment to Il-23 License Agreement With Paragon Therapeutics - SEC Filing

THOMSON REUTERS
·
Jun 02

Oruka Therapeutics - Amendment Expands Field to All Uses With Dosing Restrictions for Inflammatory Bowel Disease - SEC Filing

THOMSON REUTERS
·
Jun 02